Development a novel nomogram model for predicting significant hepatic histological changes in chronic hepatitis B virus carriers

• Published in: Journal of medical virology 2023-07, Vol.95 (7), p.e28943-n/a
• Main Authors: Kang, Na‐Ling, Gao, Ya‐Hong, Lin, Meng‐Xin, Wu, Lu‐Ying, Ye, Xiang‐Yang, Lin, Hui‐Ming, Ruan, Qing‐Fa, Lin, Shuo, Liu, Hao‐Hang, Huang, Ling‐Ling, Jiang, Jia‐Ji, Liu, Yu‐Rui, Zheng, Qi, Mao, Ri‐Cheng, Zeng, Da‐Wu
• Format: Article
• Language: English
• Subjects: Alanine; Alanine Transaminase; Antigens; chronic HBV carriers; DNA, Viral; Hepatitis; Hepatitis B; Hepatitis B e Antigens; Hepatitis B surface antigen; Hepatitis B virus - genetics; Hepatitis B, Chronic - diagnosis; Hepatitis B, Chronic - pathology; hepatitis virus B; Humans; Liver Cirrhosis - diagnosis; liver histology; LSM; nomogram; Nomograms; Performance prediction; Statistical analysis; Training; Virology; Viruses; γ-Glutamyltransferase
• ISSN: 0146-6615; 1096-9071
• DOI: 10.1002/jmv.28943

A proportion of chronic hepatitis B virus (HBV) carriers with normal alanine transaminase (ALT) present with significant liver histological changes (SLHC). To construct a noninvasive nomogram model to identify SLHC in chronic HBV carriers with different upper limits of normal (ULNs) for ALT. The training cohort consisted of 732 chronic HBV carriers who were stratified into four sets according to different ULNs for ALT: chronic HBV carriers I, II, III, and IV. The external validation cohort comprised 277 chronic HBV carriers. Logistic regression and least absolute shrinkage and selection operator analyses were applied to develop a nomogram model to predict SLHC. A nomogram model‐HBGP (based on hepatitis B surface antigen, gamma‐glutamyl transpeptidase, and platelet count) demonstrated good performance in diagnosing SLHC with area under the curve (AUCs) of 0.866 (95% confidence interval [CI]: 0.839−0.892) and 0.885 (95% CI: 0.845−0.925) in the training and validation cohorts, respectively. Furthermore, HBGP displayed high diagnostic values for SLHC with AUCs of 0.866 (95% CI: 0.839−0.892), 0.868 (95% CI: 0.838−0.898), 0.865 (95% CI: 0.828−0.901), and 0.853 (95% CI: 0.798−0.908) in chronic HBV carriers I, II, III, and IV, respectively. Additionally, HBGP showed greater ability in predicting SLHC compared with the existing predictors. HBGP has shown high predictive performance for SLHC, and thus may lead to an informed decision on the initiation of antiviral treatment.